Universal Journal of Pharmaceutical Research · 2019 · 14 citations · 17 references
Public HealthInfectious DiseasesMicrobiologyAntimicrobial ResistanceDiagnostic MicrobiologyMedical MicrobiologyMolecular Epidemiology Of ResistancePulmonary TuberculosisTuberculosis DiagnosisTuberculosis Diagnostic TestingTuberculosis EpidemiologyTuberculosis SurveillanceDrug Resistance TestingMolecular Detection AssaysPhenotypic Drug Susceptibility TestingResistance Risk FactorsRifampicin Resistance TestingSputum ExaminationSputum MicrobiologyTuberculosis Drug Resistance
The current study was undertaken in Sana'a city, Yemen, which has one of the highest rates of Tuberculosis (TB) in the Region. The aims of this retrospective study were determined the prevalence of true RIF's mono-resistance, using the gold standard of molecular assays comparing with culture based phenotypic drug susceptibility testing (DST), and determined the associated risk factors of contracting RF gene among Yemeni TB patients. Patient's data were collected in a predesigned questionnaire which included demographic information and the relevant risk factors associated with RIF. All sputum specimens received were routinely cultured, and, underwent phenotypic drug susceptibility testing. DNA sequences specific for MTB and RIF were detected by automated molecular test. The total end treatment rate was 5.94% of the total cases (11/185). MTB gene was positive for all cases which indicate more sensitive than sputum examination; 3.2% of total patients show RIF's genes positive. Higher rate of RIF with male (5.4%), and low in female patients (1.8%). There was higher rate of RIF with age group 36-45 years (8.7%) and >15 years (7.1%). There was significant rate of RIF gene with after food drug taken (RIF=13.3%, with Odds ratio (OR)=6.4), and with DOTs program (RIF=10%, with OR=6.4). In addition, there was significant rate of RIF gene with one dose regimen (11.8%, OR=5.5). In conclusion, this study reveals the presence of RIF- M. tuberculosis in Sana’a, Yemen and most of them were observed among patients who default treatment. This is considered as a threat to TB control programme and it is recommended that strategies should be put in place in order to ensure patients’ compliance and monitoring of patients’ response to TB treatment.
17
Structural Mechanism for Rifampicin Inhibition of Bacterial RNA Polymerase
Elizabeth A. Campbell, Nataliya Korzheva, Arkady Mustaev et al. · Cell · 2001 · 1.5K citations · Full text
Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis
Amalio Telenti, Paul Imboden, Federica Marchesi et al. · The Lancet · 1993 · 1.3K citations
Danica Helb, Martin Jones, Elizabeth Story‐Roller et al. · Journal of Clinical Microbiology · 2009 · 920 citations · Full text
Amalio Telenti, Nadine Honoré, C. Bernasconi et al. · Journal of Clinical Microbiology · 1997 · 324 citations · Full text